Neurocrine Biosciences In... (NBIX)
NASDAQ: NBIX
· Real-Time Price · USD
124.63
1.61 (1.31%)
At close: Jun 02, 2025, 3:59 PM
123.01
-1.30%
Pre-market: Jun 03, 2025, 07:26 AM EDT
Neurocrine Biosciences Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Collaboration Revenue Revenue | 24.7M | 26.5M | 47.8M | 43.4M | 51.8M | 35.19M | 41.63M |
| Collaboration Revenue Revenue Growth | -6.79% | -44.56% | +10.14% | -16.22% | +47.21% | -15.48% | n/a |
| Product Revenue | 2.33B | 1.86B | 1.44B | 1.09B | 994.1M | 752.9M | 409.61M |
| Product Revenue Growth | +25.26% | +29.13% | +32.18% | +9.66% | +32.04% | +83.81% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 276.5M | 287.8M | 234.3M | 242M | 243.1M | 218.9M | 204.2M | 221.8M | 242.7M | 182.9M | 186.3M | 182.8M | 200.7M | 156.5M | 154.6M | 143.2M | 129M | 106.5M | 112.5M | 96.5M | 117.8M | 101.3M | 84.49M | 80.82M | 87.54M | 68.98M | 60.4M | 60.91M | 58.64M | 56.31M | 43.87M | 41.67M | 28.05M | 23.67M | 17.49M | 14.96M | 11.95M | 8.94M | 11.46M | 6.6M | 5.48M |
| Selling, General, and Administrative Revenue Growth | -3.93% | +22.83% | -3.18% | -0.45% | +11.06% | +7.20% | -7.94% | -8.61% | +32.70% | -1.83% | +1.91% | -8.92% | +28.24% | +1.23% | +7.96% | +11.01% | +21.13% | -5.33% | +16.58% | -18.08% | +16.29% | +19.90% | +4.53% | -7.67% | +26.90% | +14.20% | -0.84% | +3.89% | +4.13% | +28.35% | +5.28% | +48.57% | +18.51% | +35.29% | +16.90% | +25.19% | +33.73% | -21.97% | +73.50% | +20.45% | n/a |
| Research and Development Revenue | 263.2M | 185.6M | 195M | 184.7M | 154.1M | 137.5M | 142.2M | 145.8M | 139.5M | 118M | 107.7M | 135.9M | 102.2M | 87.4M | 92.7M | 74.8M | 73.2M | 66.7M | 69.1M | 80.9M | 58.3M | 55.3M | 45.28M | 61.69M | 37.65M | 39.11M | 35.48M | 36.99M | 48.95M | 25.61M | 22.46M | 21.87M | 51.88M | 22.58M | 20.94M | 26.86M | 23.9M | 21.81M | 24.39M | 18.72M | 16.57M |
| Research and Development Revenue Growth | +41.81% | -4.82% | +5.58% | +19.86% | +12.07% | -3.31% | -2.47% | +4.52% | +18.22% | +9.56% | -20.75% | +32.97% | +16.93% | -5.72% | +23.93% | +2.19% | +9.75% | -3.47% | -14.59% | +38.77% | +5.42% | +22.13% | -26.60% | +63.83% | -3.72% | +10.22% | -4.07% | -24.43% | +91.09% | +14.03% | +2.72% | -57.85% | +129.74% | +7.84% | -22.04% | +12.38% | +9.60% | -10.57% | +30.28% | +12.94% | n/a |